Details for Patent: 9,144,559
✉ Email this page to a colleague
Which drugs does patent 9,144,559 protect, and when does it expire?
Patent 9,144,559 protects LYRICA CR and is included in one NDA.
Protection for LYRICA CR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-seven patent family members in thirty-three countries.
Summary for Patent: 9,144,559
Title: | Solid pharmaceutical compositions containing pregabalin |
Abstract: | A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. |
Inventor(s): | Bockbrader; Howard N. (Ann Arbor, MI), Cho; Yun Hyung (Lexington, MA), Diaz Santiago; Steven (Martinsville, NJ), Mahjour; Majid (Schwenksville, PA), Reynolds; Thomas Daniel (Morgantown, WV), Shao; Pushpa Ganapathi (San Diego, CA), Shao; Zezhi Jesse (San Diego, CA), Wan; Jiansheng (Short Hills, NJ) |
Assignee: | Warner-Lambert Company LLC (New York, NY) |
Application Number: | 14/570,115 |
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; |
Drugs Protected by US Patent 9,144,559
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Upjohn | LYRICA CR | pregabalin | TABLET, EXTENDED RELEASE;ORAL | 209501-001 | Oct 11, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Upjohn | LYRICA CR | pregabalin | TABLET, EXTENDED RELEASE;ORAL | 209501-002 | Oct 11, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Upjohn | LYRICA CR | pregabalin | TABLET, EXTENDED RELEASE;ORAL | 209501-003 | Oct 11, 2017 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,144,559
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 058175 | ⤷ Sign Up | |||
Australia | 2006310217 | ⤷ Sign Up | |||
Brazil | PI0618211 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |